Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial - PACE-CME

Efficacy and safety of ARNI in highrisk patients in the PIONEERHF trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
Effects of finerenone on HF readmissions
Effects of finerenone on HF readmissions
ESC Heart Failure 2025
Effects of finerenone on HF readmissions
- Ankeet Bhatt, MD
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
ESC Heart Failure 2025
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
- João Pedro Ferreira, MD, PhD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD